AavantiBio: Solid Bio yields to Sarepta on Duchenne with plans for merger, R&D shakeup
The biotech, which fell behind Sarepta in developing a Duchenne gene therapy, will merge with AavantiBio, a gene therapy startup run by a former Sarepta executive.
Read full article »
AavantiBio is a Massachusetts-based biotechnology company that develops gene therapies for the treatment of cardiac and central nervous system dysfunctions.
Read more